Latest News for: yarrow

Edit

Material Agreement (Form 8-K) (Yarrow Bioscience Inc)

Public Technologies 14 Sep 2026
) Item 1.01 Entry into a Material Definitive Agreement. On September 10, 2026, Yarrow Bioscience, Inc ... The securities described above were offered pursuant to the Company's shelf registration statement on Form S-3 (File No ... Yarrow Bioscience Inc ... (noodl.
Edit

Supplemental Prospectus (Form 424B5) (Yarrow Bioscience Inc)

Public Technologies 11 Sep 2026
Proceeds, Before Expenses, to Yarrow Bioscience, Inc ... (formerly known as Yarrow Bioscience, Inc.) ("Pre-Merger Yarrow") ... (changed to Yarrow Bioscience, Inc ... The financial statements of Yarrow Bioscience, Inc ... Yarrow Bioscience, Inc.
Edit

Material Event (Form 8-K) (Yarrow Bioscience Inc)

Public Technologies 10 Sep 2026
). The text version of this document is not available ... Yarrow Bioscience Inc.
Edit

VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience

Nasdaq Globe Newswire 10 Jul 2026
Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share. Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share ... .
Edit

VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience (Form 8-K) (Vyne Therapeutics Inc)

Public Technologies 10 Jul 2026
Proposed Merger with Yarrow Bioscience ... ("Yarrow") pursuant to the Agreement and Plan of Merger and Reorganization, dated December 17, 2025 (as amended, the "Merger Agreement") ... About Yarrow Bioscience, Inc.
  • 1
×